Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that three of its products have been included in China’s National Reimbursement Drug List, which could enhance their market accessibility and potentially boost the company’s revenue. Additionally, the company has entered into new framework agreements for promotional services, R&D, and procurement, which are expected to strengthen its operational capabilities and align with regulatory requirements, impacting its stakeholder engagement and market positioning.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and production of innovative drugs. The company is involved in the creation of antibody-drug conjugates (ADCs) and other pharmaceutical products, with a market focus on providing advanced therapeutic solutions.
Average Trading Volume: 642,426
Technical Sentiment Signal: Buy
Current Market Cap: HK$102.3B
See more data about 6990 stock on TipRanks’ Stock Analysis page.